Estimated Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared to Optimally Acenocoumarol Anticoagulated ‘Real-World’ in Patients With Atrial Fibrillation by Esteve-Pastor, María Asunción et al.
 
 
University of Birmingham
Estimated Effectiveness and Safety of Non-Vitamin
K Antagonist Oral Anticoagulants Compared to
Optimally Acenocoumarol Anticoagulated ‘Real-
World’ in Patients With Atrial Fibrillation
Esteve-Pastor, María Asunción; Rivera-Caravaca, José Miguel; Roldán, Vanessa; Orenes-
Piñero, Esteban; Romiti, Giulio Francesco; Romanazzi, Imma; Bai, Ying; Carmo, João;
Proietti, Marco; Marín, Francisco; Lip, Gregory
DOI:
10.1016/j.amjcard.2018.05.012
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Esteve-Pastor, MA, Rivera-Caravaca, JM, Roldán, V, Orenes-Piñero, E, Romiti, GF, Romanazzi, I, Bai, Y,
Carmo, J, Proietti, M, Marín, F & Lip, G 2018, 'Estimated Effectiveness and Safety of Non-Vitamin K Antagonist
Oral Anticoagulants Compared to Optimally Acenocoumarol Anticoagulated ‘Real-World’ in Patients With Atrial
Fibrillation', The American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2018.05.012
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
 Accepted Manuscript
Estimated Effectiveness and Safety of Non-Vitamin K Antagonist Oral
Anticoagulants Compared to Optimally Acenocoumarol
Anticoagulated ‘Real-World’ in Patients With Atrial Fibrillation
Marı´a Asuncio´n Esteve-Pastor MD ,
Jose´ Miguel Rivera-Caravaca RN MSc , Vanessa Rolda´n MD PhD ,
Esteban Orenes-Pin˜ero PhD , Giulio Francesco Romiti MD ,
Imma Romanazzi MD , Ying Bai PhD , Joa ̃o Carmo MD ,
Marco Proietti MD , Francisco Marı´n MD PhD ,
Gregory Y.H. Lip MD
PII: S0002-9149(18)31184-6
DOI: 10.1016/j.amjcard.2018.05.012
Reference: AJC 23316
To appear in: The American Journal of Cardiology
Received date: 25 February 2018
Revised date: 29 April 2018
Accepted date: 1 May 2018
Please cite this article as: Marı´a Asuncio´n Esteve-Pastor MD , Jose´ Miguel Rivera-Caravaca RN MSc ,
Vanessa Rolda´n MD PhD , Esteban Orenes-Pin˜ero PhD , Giulio Francesco Romiti MD ,
Imma Romanazzi MD , Ying Bai PhD , Joa ̃o Carmo MD , Marco Proietti MD ,
Francisco Marı´n MD PhD , Gregory Y.H. Lip MD , Estimated Effectiveness and Safety of Non-
Vitamin K Antagonist Oral Anticoagulants Compared to Optimally Acenocoumarol Anticoagulated
‘Real-World’ in Patients With Atrial Fibrillation, The American Journal of Cardiology (2018), doi:
10.1016/j.amjcard.2018.05.012
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service
to our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and
all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 1 
Estimated Effectiveness and Safety of Non-Vitamin K Antagonist Oral 
Anticoagulants Compared to Optimally Acenocoumarol Anticoagulated ‘Real-
World’ in Patients With Atrial Fibrillation. 
Running title: Estimated Effect of NOACs in ‘Real-World’ AF Patients 
 
María Asunción Esteve-Pastor
1,2
 MD; José Miguel Rivera-Caravaca
1,3
 RN MSc; 
Vanessa Roldán
3
 MD PhD; Esteban Orenes-Piñero
2
 PhD; Giulio Francesco Romiti
1
 
MD; Imma Romanazzi
1
 MD; Ying Bai
1,4
 PhD; João Carmo5 MD; Marco Proietti1,6 MD; 
Francisco Marín
2*
 MD PhD; Gregory Y.H. Lip
1,7*
 MD. 
[*joint senior authors] 
 
1
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United 
Kingdom. 
2
Department of Cardiology, Hospital Clínico Universitario Virgen de la 
Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBER-
CV, Murcia, Spain. 
3
Department of Hematology and Clinical Oncology, Hospital 
General Universitario Morales Meseguer, University of Murcia, Instituto Murciano de 
Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain. 
4
Cardiovascular Center, 
Beijing Tongren Hospital, Capital Medical University, China. 
5
Cardiology Department, 
Santa Cruz Hospital, Western Lisbon Hospital Centre, Portugal. 
6
IRCCS – Istituto di 
Ricerche Farmacologiche Mario Negri, Department of Neuroscience, Milan, 
Italy. 
7
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg 
University, Aalborg, Denmark. 
 
 
Address for correspondence 
Francisco Marín 
Department of Cardiology 
Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca 
Ctra. Madrid-Cartagena s/n 30120, Murcia, Spain. 
Tel./fax: +34 968 38 10 27; E-mail: fcomarino@hotmail.com  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 2 
ABSTRACT 
Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as an 
alternative to vitamin K antagonists in atrial fibrillation (AF) patients but the 
comparative benefits between NOACs and optimally anticoagulated patients is 
unknown. We estimated the absolute benefit in clinical outcomes rates of real-world 
(RW) effect of NOACs in optimally anticoagulated AF patients with acenocoumarol. 
We included 1,361 patients stable on acenocoumarol with time in therapeutic range of 
100% and 6.5 years of follow-up. Estimation of clinical events avoided was calculated 
applying hazard ratio, absolute and relative risk reduction from the RW meta-analysis. 
Compared to an optimally anticoagulated population, dabigatran 110mg had the highest 
estimated stroke reduction (0.97%/year vs 1.47%/year; p=0.002), and the benefit was 
higher than in RE-LY trial. For major bleeding, apixaban showed the highest estimated 
reduction (1.81%/year vs 2.83%/year; p<0.001). For mortality, the largest estimated 
reduction was with apixaban (2.68%/year). For gastrointestinal bleeding, only apixaban 
had a significant reduction compared to acenocoumarol (0.69%/year vs 1.10%/year; 
p=0.004), and the reduction was significantly higher than in ARISTOTLE trial. All 
NOACs showed significantly lower rates for intracranial haemorrhage and had a 
positive Net Clinical Benefit (NCB) compared to acenocoumarol. Apixaban showed the 
highest extended estimated NCB 2.64 (95%CI 2.34-2.96). In conclusion, in optimally 
acenocoumarol anticoagulated AF patients, estimated reductions in all clinical outcomes 
with various NOACs are evident, with the best effectiveness and safety profile with 
apixaban. Indeed, the estimated effect with “real world” NOACs would probably be 
higher than that seen in phase-III clinical trials. 
Key words: non-vitamin K oral anticoagulants, vitamin K antagonists, atrial 
fibrillation, real-world  
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INTRODUCTION 
For many years, vitamin K antagonists (VKAs) have been the only effective oral 
treatment to reduce thromboembolic events and mortality in Atrial Fibrillation (AF) 
patients(1). Indeed, it is necessary to achieve high TTR (i.e.> 70%) to maximize the 
efficacy and safety of VKA treatment(2), but this is the main limitation of VKA therapy 
due to its narrow therapeutic window (3). The non-vitamin K antagonist oral 
anticoagulants (NOACs) have emerged as an effective and safer alternative to VKAs 
(4–7). However, the effect of NOACs in clinical trials may not be the same as in ‘real-
world’ (RW) practice and the results from RW data studies provide better generalisation 
of results(8). Currently, there are only four meta-analysis with RW observational data 
that compare the effect of NOACs and VKAs (9–12).Despite of the effectiveness and 
safety profile of NOACs even in RW AF patients, VKAs have remained widely used in 
clinical practice worldwide and many healthcare systems do not implement a first-line 
strategy with NOACs due to costs. Some studies have even proposed that optimally 
managed VKA therapy is a valid alternative for AF patients and could be as efficacious 
as NOACs (13,14), but a comparison between RW effect of NOACs with optimal 
management of VKA in AF patients is unknown. The main objective of our study is to 
estimate the absolute benefit of NOACs based on RW data on clinical outcomes in a 
cohort of optimally anticoagulated AF patients with acenocoumarol. 
 
METHODS 
We included all consecutive outpatients with confirmed diagnosis of AF 
(paroxysmal, persistent and permanent AF) treated in our anticoagulation clinic in the 
Southeast Spain from May 2007 to December 2007. The inclusion criteria were patients 
older than 18 years old with confirmed diagnosis of AF who were stable on 
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acenocoumarol treatment during at least the 6 previous months. At entry, all patients 
had time in therapeutic range as measured by the Rosendaal method (15) of 100% to 
ensure our inclusion of a homogeneous cohort of optimally managed AF patients on 
acenocoumarol treatment. The exclusion criteria were hospital admission, acute 
coronary syndrome, surgical interventions or hemodynamic instability during the 
preceding 6 months. Patients with moderate-severe rheumatic mitral disease of 
prosthetic heart valve disease were also excluded. 
At entry, complete medical history of each patient was collected with clinical and 
demographic characteristics. Blood samples were also collected at inclusion visit. 
Thromboembolic risk was calculated with CHA2DS2-VASc score (16) and bleeding risk 
was calculated with HAS-BLED score (17). All patients received anticoagulation 
therapy with acenocoumarol (the commonest VKA used in Spain) and all patients at 
entry had all their INR in therapeutic range (between 2.0 and 3.0) during the previous 6 
months.  
Follow-up was conducted through personal visits to the anticoagulation clinic and 
started the day of the inclusion, with no patients lost of follow-up. Adverse 
thromboembolic events (stroke/transitory ischaemic attack), cardiovascular mortality, 
all-cause mortality, major bleeding, intracranial bleeding and gastrointestinal bleeding 
were collected. Major bleeding events were defined according to the 2005 International 
Society of Thrombosis and Haemostasis criteria(18). 
All patients provided signed informed consent to participation in the study. The 
study was conducted according the ethical principles of Declaration of Helsinki and 
Good Clinical Practice Guidelines and was approved by the Ethics Committee from 
University Hospital Morales Meseguer (Murcia, Spain).  
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All statistical analyses were performed retrospectively, although our dataset was 
collected prospectively.Continuous variables were tested for normality with 
Kolmogorov-Smirnov test and presented as mean ± standard deviation or median 
[interquartile range, IQR]. Categorical variables are expressed as percentages. The Chi-
square test was used to compare proportions. 
Estimation of potential real-world effect of NOACs 
We calculated the estimated rates for stroke, major bleeding, gastrointestinal 
bleeding, intracranial haemorrhage and all-cause mortality using NOACs instead of 
acenocoumarol by multiplying the pooled Hazard Ratios (HR) obtained for each clinical 
adverse event from the three meta-analyses providing the estimated effect seen in RW 
of dabigatran(10), rivaroxaban(11) and apixaban(12) against the RW rates seen amongst 
our optimally anticoagulated patients with acenocoumarol after follow-up. We 
personally contacted with the main investigators of each meta-analyses to know the 
selection strategy of the studies included in the meta-analyses to calculate the different 
HR for each clinical event. We also compared differences between our reference real 
rates to the estimated RW effect and with the estimated effect in clinical trials using the 
Hazard Ratios (HRs) from RE-LY(4), ROCKET(6) and ARISTOTLE(5) clinical trials. 
We also calculated the absolute risk reduction (ARRs), relative risk reduction (RRRs) 
and number needed to treat (NNTs). We calculated the estimated absolute numbers of 
all adverse clinical events that theoretically might be avoided by using dabigatran, 
rivaroxaban and apixaban instead of acenocoumarol by multiplying the RRRs from RW 
meta-analysis by the event rates of our anticoagulated population. The resulting ARRs 
were used to calculated the NNTs to prevent one adverse event as Amin et al. 
previously performed(19). 
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We evaluated the weighed net clinical benefit of the estimated use of each NOAC 
compared to acenocoumarol. We evaluated the crude incidence rate (IR) per 100 
patient-years of each weighted event for patients for patients receiving acenocoumarol 
and the estimated crude incidence rate for each NOAC. 
We calculated both, using the standardized weights proposed by Singer et al.(20) 
(1.5 for ICH) and using our own weights associated with major bleeding, ICH and 
gastrointestinal bleeding using stroke as a reference(21). (Appendix 1 and 
Supplementary Table 2). 
Statistical significance was defined as p<0.05 and 95% confidence intervals were 
calculated for all the analyses. Statistical analyses were performed with SPSS version 
22.0 (SPSS Inc, Chicago, IL, USA) and MedCalc v. 16.4.3 (MedCalc Software bvba, 
Ostend, Belgium) statistical packages for Windows. 
 
RESULTS 
Baseline characteristics of AF population are summarized in Supplementary 
Table 1. We enrolled 1,361 AF patients [median age 76, IQR (71-81) years; 663 
(48.7%) males]. 1,116 (82.0%) patients had hypertension, 267 (15.9%) had previous 
stroke and 113 (8.3%) previous bleeding. After 6.5 [IQR 4.3-7.9] years of follow-up, 
130 (1.47%/year) patients had stroke/transitory ischaemic attack, 78 (0.88%/year) 
patients had ICH, 97 (1.10%/year) had gastrointestinal bleeding and 250 (2.83%/year) 
had major bleeding events. Also, 551 (6.23%/year) patients died during the follow-up. 
The estimated effect of each NOAC in RW, in phase III clinical trials and the 
estimated reduction compared acenocoumarol, RW NOACs and phase III clinical trials 
are shown in Table 1 for dabigatran, Table 2 for rivaroxaban and Table 3 for apixaban; 
and Figure 1 and Figure 2. 
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We estimated that the rates for stroke using RW NOACs would be 1.34%/year for 
dabigatran 150 mg, 0.97%/year for dabigatran 110mg, 1.26%/year for rivaroxaban and 
1.23%/year for apixaban. In phase III clinical trials, Dabigatran 150 mg had the highest 
estimated reduction for stroke (0.94% vs 1.47%; p=0.001).  
Based on the RW effect, Dabigatran 110 mg was the only NOAC that showed 
significantly lower stroke rate compared with optimally management of AF with 
acenocoumarol (0.97%/year vs 1.47%/year; p=0.002) and this effect in RW was higher 
than that expected in the RE-LY clinical trial (0.97%/year vs 1.35%/year; p=0.017). 
Using dabigatran 110 mg instead of acenocoumarol, 0.50 stroke events per 100 patient-
years (i.e.45 strokes avoided over the total sample) would be avoided, resulting in a 
NNT of 204 for avoiding 1 stroke. The use of dabigatran 110 mg in RW showed an 
estimated benefit effect on stroke prevention of 135% (95%CI 127%-143%) compared 
with the full effect of acenocoumarol. 
We estimated that the rates of all-cause mortality using RW NOACs would be 
4.36%/year for dabigatran 150mg, 4.92%/year for dabigatran 110mg, 6.48%/year for 
rivaroxaban and 3.55%/year for apixaban. We observed significantly lower mortality 
rates with dabigatran 150mg, dabigatran 110 mg and apixaban than with optimally 
management with acenocoumarol. Indeed, the effect observed in RW NOACs was 
significantly higher than in phase III clinical trials for these NOACs. For rivaroxaban, 
there was a trend to higher mortality in RW use.  
Compared to the optimally anticoagulated AF patients on acenocoumarol, 
apixaban showed the highest significant reduction in mortality with 2.68 deaths per 100 
patient-years (237 deaths avoided over the total sample, i.e. 43% deaths less) would be 
avoided using apixaban instead of acenocoumarol with optimally management, 
resulting in a NNT of 37 to avoid 1 death. The use of apixaban in RW showed an 
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estimated benefit effect on mortality prevention of 143% (95%CI 139-147) compared 
with the full effect of acenocoumarol. 
We estimated that the rates of major bleeding would be 2.29%/year for dabigatran 
150 mg, 2.12%/year for dabigatran 110 mg, 2.80%/year for rivaroxaban and 1.81%/year 
with apixaban. We observed a significant reduction in major bleeding using dabigatran 
150 mg, dabigatran 110 mg and apixaban instead of optimally management with 
acenocoumarol. The significantly highest reduction was observed with apixaban with 
1.02 major bleeding per 100 patient-years (i.e. 90 bleeding events avoided over total 
sample) that would be avoided resulting in a NNT of 101 to avoid 1 major bleeding 
using apixaban instead of acenocoumarol. The use of apixaban in RW showed an 
estimated benefit effect on major bleeding prevention of 136% (95%CI 130-142) 
compared with the full effect of acenocoumarol. 
We observed that all NOACs showed significantly lower ICH rates in comparison 
with the optimally management VKA therapy with acenocoumarol and the effect in RW 
was similar than the observed in clinical trials. The estimated highest event reduction 
was observed with dabigatran 150 mg and 0.50 intracranial bleeding events per 100 
patient-years (i.e. 44 bleeding events avoided over total sample) would be avoided using 
dabigatran 150 mg instead of acenocoumarol resulting in a NNT of 182 to avoid 1 ICH 
using dabigatran instead of acenocoumarol. The use of dabigatran 150 mg in RW 
showed an estimated benefit effect on ICH prevention of 156% (95%CI 145-167) 
compared with the full effect of acenocoumarol. 
The estimated rates of RW NOAC for gastrointestinal bleeding were 1.30%/year 
for dabigatran 150 mg, 1.06%/year for dabigatran 110 mg, 1.32%/year for rivaroxaban 
and 0.69%/year for apixaban. Apixaban was the only NOAC that showed significantly 
estimated reduction effect for gastrointestinal bleeding in comparison with 
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acenocoumarol (1.10%/year vs 0.69%/year; p=0.004) and the effect was significantly 
higher than it would be expected in the clinical trial. Therefore 0.41 gastrointestinal 
bleeding events per 100 patient-years (i.e. 36 bleeding events avoided over total sample) 
would be avoided using apixaban instead of acenocoumarol resulting in a NNT of 263 
to avoid 1 gastrointestinal bleeding using apixaban. The use of apixaban in RW showed 
an estimated benefit effect on gastrointestinal bleeding prevention of 137% (95%CI 
128-147) compared with the full effect of acenocoumarol. 
Table 4 shows the net clinical benefit (NCB) of acenocoumarol versus each 
NOAC by stroke and ICH, and by stroke and all significant bleeding events. All 
NOACs were predicted to have a positive NCB balancing stroke against ICH and a 
positive NCB balancing stroke against all significant bleeding events. Dabigatran 110 
mg had the highest positive NCB balancing stroke against ICH while Apixaban was the 
NOAC with the highest positive NCB balancing stroke against all significant bleeding 
events.  
 
DISCUSSION 
In an optimally acenocoumarol anticoagulated AF patients, estimated reductions 
in all clinical outcomes with various NOACs are evident. In RW, dabigatran 110 mg 
showed the highest reduction in stroke rates and apixaban showed the highest effect on 
mortality, major bleeding and gastrointestinal bleeding in comparison with 
acenocoumarol, with also the highest positive NCB. Thus, the effect of “real-world” 
NOACs showed an improvement in both effectiveness and safety profile even in 
optimally VKA anticoagulated AF patients, higher than in phase III clinical trials.  
In our analyses, we performed an estimated rate of events (ie the estimated rates if 
the patients had been treated with NOACs instead of acenocoumarol) because in clinical 
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practice is unlikely to make a real comparison between optimally anticoagulated 
patients with VKA and NOACs to assess the different adverse events with long follow-
up (6.5 years).  
Ischemic stroke risk reduction was only observed with Dabigatran 150 mg 
compared with warfarin in the RE-LY(4) clinical trial whereas dabigatran 110 mg was 
non-inferior to warfarin for stroke. In the ARISTOTLE trial, apixaban was superior to 
warfarin in preventing stroke/SE whereas rivaroxaban was noninferior to warfarin for 
the prevention of stroke/SE. Korenstra et al.(22) compared dabigatran with 
acenocoumarol and they did not find significant differences between both treatments 
where VKA patients were well managed, with a mean TTR of 78%. In our study, 
comparing with the full effect of acenocoumarol, the use of dabigatran 110 mg in RW 
showed an estimated benefit effect on stroke prevention of 135% and the estimated 
effect was higher in RW than that expected from the clinical trial. All NOACs in their 
phase III clinical trials and in the RW data showed lower rates of ICH in comparison 
with warfarin and we also observed a significant estimated reduction of ICH with all 
NOACs. For major bleeding events, different safety profiles have been observed 
between the NOACs(23). Lip et al.(24) conducted a RW comparison of major bleeding 
between NOACs and showed that apixaban and dabigatran initiation was associated 
with lower risk of major bleeding and rivaroxaban had higher risk compared to 
warfarin. We observed that the use of apixaban in RW showed an estimated benefit 
effect on major bleeding prevention of 136% compared with the full effect of 
acenocoumarol. When focused on gastrointestinal bleeding, apixaban had the highest 
estimated reduction and the effect was higher than the expected in its clinical trial, with 
an estimated benefit of apixaban treatment of 137%.  
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We also noted significantly lower expected rates for mortality with dabigatran and 
apixaban. Indeed, apixaban had the highest estimated reduction in mortality. These 
findings are consistent with the results of previous observational studies in which the 
benefits of dabigatran and apixaban in mortality were greater over VKAs(25,26). 
Although our patients had higher TTR than other RW data or clinical trials, we had 
higher rates of mortality due to the long-time of follow-up (6.5 years), the comorbidities 
and because our patients were treated according to daily clinical practice without 
additional care to be included in a registry. Nonetheless, our data show a greater effect 
regarding to mortality than to major bleeding. Indeed, the effect in RW on mortality is 
greater than in phase 3 clinical trials although RW patients tended to be more elderly, 
with more comorbidities and thus, a higher risk of death. Banerjee et al. (27) showed 
that when thromboembolic and bleeding risk are both high, NOACs appear to have a 
great NCB compared to warfarin. In our analysis, we estimated positive NCB for all 
NOACs with the greatest effect for the combined outcomes of stroke and any significant 
bleeding seen with apixaban. 
Nonetheless, many healthcare systems do not implement a first-line strategy with 
NOACs due to costs and it is often required to start AF treatment with a VKA and only 
if they do not have good TTR after 6 months of treatment, only then it is possible to 
switch to NOACs (28,29). Data from Swedish national quality registries (13) reported 
less rates of adverse clinical outcomes in well-managed AF patients with TTR higher 
than 70%. Indeed, recent studies(14) proposed that VKA treatment with high TTR 
could be as efficacious as NOACs given that the main benefits of NOACs compared 
with warfarin may be only marginal in those patients with high TTR. Carmo et al.(30) 
conducted a meta-analysis of the effect of NOACs compared with warfarin at different 
levels of TTR and showed that the superiority of NOACs in stroke prevention was lost 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 12 
with TTR>70% but the risk of major bleeding was significantly lower with NOACs. We 
observed that even in the full effect of VKA treatment, NOACs reported significantly 
higher effect in all adverse events reduction. 
This study has several limitations that should be noted. Our data represent the 
observations of oral anticoagulation treatment with acenocoumarol without direct 
comparison between VKAs and NOACs, and thus, would be subject to limitations 
inherent to the methodology. All out patients were treated with acenocoumarol, which 
has a shorter half-life than warfarin (10 vs 36 h), so the estimation effect of NOACs in 
warfarin population may not be equivalent. Patients are representative of a Spanish 
population (mainly Caucasian) and thus, the results might not be extrapolated to other 
regions. Indeed, all statistical analyses were performed retrospectively although our 
dataset was collected prospectively. No observational RW studies have been performed 
with edoxaban yet, thus we did not compare it with acenocoumarol. Although we did 
not perform a direct comparison between NOACs, some care should be taken when the 
clinical results of the meta-analyses were generalized. We cannot perform a direct 
comparison using propensity score to homogenize the baseline characteristics then we 
assumed this limitation of our study. We did not compare differences between NOACs 
but we compared the differences between NOACs and optimal management of VKA 
therapy. To calculate the estimated rates for clinical events, we used the hazard ratio 
from clinical trials and from the three meta-analyses. Although the study quality of the 
manuscripts included to perform all these three meta-analyses was assessed according to 
the Newcastle-Ottawa scale, potential biases were linked to the inherent methodology of 
the meta-analyses (inclusion and exclusion criteria of each study, events available, 
heterogeneity…). 
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In conclusion, in optimally acenocoumarol anticoagulated AF patients, estimated 
reductions in all clinical outcomes with various NOACs are evident from our analysis. 
In RW, Dabigatran 110 mg showed the highest reduction in stroke rates and apixaban 
showed the highest effect on mortality, major bleeding and gastrointestinal bleeding in 
comparison with acenocoumarol, with also the highest positive net clinical benefit. 
Indeed, the effect in “real-world” NOACs was higher than in phase 3 clinical trials. 
Thus, the effect of “real-world” NOACs showed an improvement in both effectiveness 
and safety profile even in optimally anticoagulated AF patients on VKA.  
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FIGURE LEGENDS 
 
 
 
 
Figure 1: Estimated effect of VKA and NOACs on the effectiveness outcomes. 
a) Stroke 
b) All-cause mortality 
 
RW: “Real-World”. VKA: Vitamin K Antagonists. NOAC: non-vitamin k oral antagonist oral 
anticoagulants.  
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Figure 2: Estimated effect of VKA and NOACs on the safety outcomes. 
a) Major bleeding 
b) Intracranial Haemorrhage 
c) Gastrointestinal Bleeding 
RW: “Real-World”. VKA: Vitamin K Antagonists. NOAC: non-vitamin k oral antagonist oral 
anticoagulants. 
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Table 1: Estimated effect of Dabigatran 150 mg and dabigatran 110 mg.  
 
 
Acenocoumarol 
 
Dabigatran 150mg 
RE-LY 
Dabigatran 150 mg 
RW 
Acenocoumarol vs  
Dabigatran 150 
mg RE-LY 
p value 
Acenocoumarol vs 
Dabigatran 150 mg 
RW 
p value 
RW 
vs 
RE-LY 
NNT 
Stroke (n) 130  83 118 
0.001 0.446 0.014 213 
% year (95%CI %/year) 1.47% (1.25%-1.73%) 0.94% (0.76%-1.15%) 1.34% (1.12%-1.58%) 
All-cause mortality (n) 551  485 386 
0.041 <0.001 <0.001 56 
% year (95%CI %/year) 6.23% (5.83%-6.63%) 5-48% (5.10%-5.88%) 4.36% (4.0%-4.74%) 
Major bleeding (n) 250 233 203 
0.439 0.027 0.150 175 
% year (95%CI %/year) 2.83% (2.52%-3.16%) 2.63% (2.34%-2.96%) 2.29% (2.02%-2.60%) 
Gastrointestinal bleeding (n) 97 146 115 
0.002 0.216 0.055 -400 
% year (95%CI %/year) 1.10% (0.90%-1.33%) 1.65% (1.41%-1.92%) 1.30% (1.09%-1.55%) 
Intracranial haemorrhage (n) 78 31 34 <0.001 <0.001 0.709 182 
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% year (95%CI %/year) 0.88% (0.71%-1.09%) 0.35% (0.25%-0.49%) 0.38% (0.28%-0.53%) 
RW: “Real-World”. NNT: Number needed to treat (comparing Acenocoumarol vs Dabigatran 150 mg RW). 95% CI: 95% Confidence Interval (%/year) 
Table 1 (continued) 
 
 
Acenocoumarol 
 
Dabigatran 110mg 
RE-LY 
Dabigatran 110 mg 
RW 
Acenocoumarol vs 
Dabigatran 110 mg 
RE-LY 
p value 
Acenocoumarol vs 
Dabigatran 110 
mg RW 
p value 
RW 
vs 
RE-LY 
NNT 
Stroke (n) 130 119 85 
0.486 0.002 0.017 204 
% year (95%CI %/year) 1.47% (1.25%-1.73%) 1.35% (1.13%-1.59%) 0.97% (0.78%-1.18%) 
All-cause mortality (n) 551 502 435 
0.131 0.002 0.028 70 
% year (95%CI %/year) 6.23% (5.83%-6.63%) 5.67% (5.29%-6.07%) 4.92% (4.54%-6.31%) 
Major bleeding (n) 250 200 188 
0.018 0.003 0.542 154 
% year (95%CI %/year) 2.83% (2.52%-3.16%) 2.26% (1.99%-2.57%) 2.12% (1.86%-2.42%) 
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Gastrointestinal bleeding (n) 97 107 94 
0.483 0.828 0.359 189 
% year (95%CI %/year) 1.10% (0.90%-1.33%) 1.21% (1.01%-1.45%) 1.06% (0.87%-1.29%) 
Intracranial haemorrhage (n) 78 24 40 
<0.001 <0.001 0.045 161 
% year (95%CI %/year) 0.88% (0.71%-1.09%) 0.27% (0.18%-0.40%) 0.45% (0.33%-0.61%) 
RW: “Real-World”. NNT: Number needed to treat (comparing Acenocoumarol vs Dabigatran 110 mg RW). 95% CI: 95% Confidence Interval (%/year) 
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Table 2: Estimated effect of Rivaroxaban 
 
 
Acenocoumarol 
 
 
Rivaroxaban 
ROCKET-AF 
 
Rivaroxaban 
RW 
 
Acenocoumarol 
vs Rivaroxaban 
ROCKET 
p value 
Acenocoumarol vs  
Rivaroxaban  
RW 
p value 
ROCKET  
vs 
RW 
NNT 
Stroke (n) 130 111 112 
0.221 0.247 0.946 526 
% year (95%CI %/year) 1.47% (1.25%-1.73%) 1.25% (1.05%-1.50%) 1.26% (1.06%-1.51%) 
All-cause mortality (n) 551 507 573 
0.176 0.517 0.046 - 95 
% year (95%CI %/year) 6.23% (5.83%-6.63%) 5.73% (5.34%-6.13%) 6.48% (6.08%-6.88%) 
Major bleeding (n) 250 260 248 
0.657 0.928 0.594 5000 
% year (95%CI %/year) 2.83% (2.52%-3.16%) 2.94% (2.63%-3.27%) 2.80% (2.50%-3.13%) 
Gastrointestinal bleeding (n) 97 142 117 
0.004 0.171 0.120 - 363 
% year (95%CI %/year) 1.10% (0.90%-1.33%) 1.61% (1.37%-1.87%) 1.32% (1.11%-1.57%) 
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Intracranial haemorrhage (n) 78 52 42 
0.022 <0.001 0.302 384 
% year (95%CI %/year) 0.88% (0.71%-1.09%) 0.59% (0.45%-0.77%) 0.48% (0.35%-0.64%) 
RW: “Real-World”. NNT: Number needed to treat (comparing Acenocoumarol vs Rivaroxaban RW). 95% CI: 95% Confidence Interval (%/year). 
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Table 3: Estimated effect of Apixaban  
 
 
Acenocoumarol 
 
Apixaban 
ARISTOTLE 
Apixaban 
RW 
Acenocoumarol 
vs Apixaban 
ARISTOTLE 
p value 
Acenocoumarol 
vs 
Apixaban RW 
p value 
ARISTOTLE 
vs 
RW 
NNT 
Stroke (n) 130 103 109 
0.076 0.174 0.680 417 
% year (95%CI %/year) 1.47% (1.25%-1.73%) 1.16% (0.97%-1.40%) 1.23% (1.03%-1.47%) 
All-cause mortality (n) 551 490 314 
0.057 <0.001 <0.001 37 
% year (95%CI %/year) 6.23% (5.83%-6.63%) 5.54% (5.15%-5.94%) 3.55% (3.22%-3.91%) 
Major bleeding (n) 250 172 160 
0.001 <0.001 0.510 101 
% year (95%CI %/year) 2.83% (2.52%-3.16%) 1.95% (1.69%-2.23%) 1.81% (1.56%-2.09%) 
Gastrointestinal bleeding (n) 97 87 61 
0.461 0.004 0.033 263 
% year (95%CI %/year) 1.10% (0.90%-1.33%) 0.98% (0.80%-1.20%) 0.69% (0.54%-0.88%) 
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Intracranial haemorrhage (n) 78 33 41 
<0.001 0.007 0.352 169 
% year (95%CI %/year) 0.88% (0.71%-1.09%) 0.37% (0.27%-0.52%) 0.46% (0.34%-0.62%) 
RW: “Real-World”. NNT: Number needed to treat. (comparing Acenocoumarol vs Apixaban. 95% CI: 95% Confidence Interval (%/year. 
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Table 4: Net clinical benefit (95% confidence interval) of NOACs versus acenocoumarol.  
 
Dabigatran 150 mg 
NCB (95%CI) 
Dabigatran 110 mg 
NCB (95%CI) 
Rivaroxaban 
NCB (95%CI) 
Apixaban 
NCB (95%CI) 
Net Clinical benefit simplified (Singer et al.) 0.88 (0.71-1.09) 1.15 (0.96-1.39) 0.87 (0.70-1.08) 0.81 (0.65-1.02) 
Net Clinical Benefit simplified 0.82 (0.65-1.02) 1.09 (0.89-1.31) 0.76 (0.60-0.95) 0.82 (0.65-1.02) 
Net clinical benefit extended 1.31 (1.10-1.56) 2.08 (1.82-2.38) 0.55 (0.42-0.73) 2.64 (2.34-2.96) 
NBC: Net clinical benefit prevented per 100 person-years (95% confidence interval).  
 
NCB simplified (Singer et al) was calculated as: (ischaemic stroke rate on acenocoumarol + 1.50 intracranial haemorrhage rate on acenocoumarol) - 
(ischaemic stroke rate on each NOAC + 1.50 intracranial haemorrhage rate on each NOAC). 
 
NCB simplified was calculated as: (ischaemic stroke rate on acenocoumarol + 1.38 intracranial haemorrhage rate on acenocoumarol) - (ischaemic stroke rate 
on each NOAC + 1.38 intracranial haemorrhage rate on each NOAC). 
 
NCB extended was calculated as: (ischaemic stroke rate on acenocoumarol + 1.38 intracranial haemorrhage rate on acenocoumarol+1. Major bleeding rate + 
gastrointestinal bleeding on acenocoumarol) - (ischaemic stroke rate on each NOAC + 1.5 intracranial haemorrhage rate on each NOAC) 
